Search

Your search keyword '"Seronde, M.F."' showing total 13 results
Start Over Author "Seronde, M.F."
13 results on '"Seronde, M.F."'

3. Cardiovascular and renal outcomes with empagliflozin in heart failure

Author

Packer, M., Anker, S.D., Butler, J., Filippatos, G., Pocock, S.J., Carson, P., Januzzi, J., Verma, S., Tsutsui, H., Brueckmann, M., Jamal, W., Kimura, K., Schnee, J., Zeller, C., Cotton, D., Bocchi, E., Böhm, M., Choi, D.J., Chopra, V., Chuquiure, E., Giannetti, N., Janssens, S., Zhang, J., Juanatey, J.R. Gonzalez, Kaul, S., Brunner-La Rocca, H.P., Merkely, B., Nicholls, S.J., Perrone, S., Pina, I., Ponikowski, P., Sattar, N., Senni, M., Seronde, M.F., Spinar, J., Squire, I., Taddei, S., Bellersen, L., Wanner, C., Zannad, F., Packer, M, Anker, S, Butler, J, Filippatos, G, Pocock, S, Carson, P, Januzzi, J, Verma, S, Tsutsui, H, Brueckmann, M, Jamal, W, Kimura, K, Schnee, J, Zeller, C, Cotton, D, Bocchi, E, Böhm, M, Choi, D, Chopra, V, Chuquiure, E, Giannetti, N, Janssens, S, Zhang, J, Gonzalez Juanatey, J, Kaul, S, Brunner-La Rocca, H, Merkely, B, Nicholls, S, Perrone, S, Pina, I, Ponikowski, P, Sattar, N, Senni, M, Seronde, M, Spinar, J, Squire, I, Taddei, S, Wanner, C, Zannad, F, Cardiologie, MUMC+: MA Med Staf Spec Cardiologie (9), and RS: Carim - H02 Cardiomyopathy

Subjects
Male, Vascular damage Radboud Institute for Health Sciences [Radboudumc 16], 030204 cardiovascular system & hematology, law.invention, 0302 clinical medicine, Randomized controlled trial, Glucosides, law, Cardiovascular Disease, Medicine, 030212 general & internal medicine, Renal Insufficiency, Chronic, Benzhydryl Compound, Sodium-Glucose Transporter 2 Inhibitor, General Medicine, Stroke volume, Middle Aged, Hospitalization, Cardiovascular Diseases, Disease Progression, Female, Type 2, Human, Glomerular Filtration Rate, medicine.medical_specialty, Glucoside, MEDLINE, Aged, Benzhydryl Compounds, Diabetes Mellitus, Type 2, Double-Blind Method, Heart Failure, Humans, Proportional Hazards Models, Renal Insufficiency, Chronic, Sodium-Glucose Transporter 2 Inhibitors, Stroke Volume, 03 medical and health sciences, All institutes and research themes of the Radboud University Medical Center, Internal medicine, Diabetes mellitus, Empagliflozin, Diabetes Mellitus, In patient, business.industry, Proportional hazards model, medicine.disease, Heart failure, Proportional Hazards Model, business
Abstract

Contains fulltext : 230126.pdf (Publisher’s version ) (Open Access) BACKGROUND: Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure in patients regardless of the presence or absence of diabetes. More evidence is needed regarding the effects of these drugs in patients across the broad spectrum of heart failure, including those with a markedly reduced ejection fraction. METHODS: In this double-blind trial, we randomly assigned 3730 patients with class II, III, or IV heart failure and an ejection fraction of 40% or less to receive empagliflozin (10 mg once daily) or placebo, in addition to recommended therapy. The primary outcome was a composite of cardiovascular death or hospitalization for worsening heart failure. RESULTS: During a median of 16 months, a primary outcome event occurred in 361 of 1863 patients (19.4%) in the empagliflozin group and in 462 of 1867 patients (24.7%) in the placebo group (hazard ratio for cardiovascular death or hospitalization for heart failure, 0.75; 95% confidence interval [CI], 0.65 to 0.86; P

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results